Search Result

Isoforms Recommended:	MHC II

Results for "

MHC-II

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MHC (4) Biochemical Assay Reagents (1) Caspase (1) Interleukin Related (1) Lactate Dehydrogenase (1) LAG-3 (7) Reactive Oxygen Species (1)
By Research Areas:	Cancer (7) Inflammation/Immunology (10) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Targets Recommended: MHC Photosystem II CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99027

Ieramilimab LAG525; IMP701	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-112026

1-Adamantaneethanol	Biochemical Assay Reagents	Inflammation/Immunology
1-Adamantaneethanol, a hapten, influences peptide binding by MHC II .

HY-W016773

1,10-Decanediol	MHC	Metabolic Disease Inflammation/Immunology
1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatory T cells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism .

HY-P99736

Miptenalimab BI-754111	LAG-3	Cancer
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (K_D: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .

HY-157280

AdCaPy	MHC	Inflammation/Immunology
AdCaPy is an *MHC II* antigen loading catalyst that accelerates the loading of peptide antigens by MHC II. AdCaPy is a useful molecular tool for enhancing immune responses .

HY-157277

AdBeSA	Others	Cancer
AdBeSA is a hapten. AdBeSA can influence peptide binding by MHC II .

HY-164308

SA-15-P	LAG-3	Inflammation/Immunology
SA-15-P inhibits *LAG-3/MHCII* and LAG-3/FGL1 interactions with IC₅₀ values of 4.21 and 6.52 μM respectively. LAG-3/MHCII interaction is a target for immunotherapies .

HY-P10835

LAG-3 cyclic peptide inhibitor C25	LAG-3	Cancer
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a K_d value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 ⁺ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .

HY-157171

Ac-YR-NH2	MHC	Inflammation/Immunology
Ac-YR-NH2 is a small molecule modulator of MHC class II antigen presentation. Ac-YR-NH2 can influence peptide binding by MHC II to influence immune response .

HY-157269

J10-1	Others	Inflammation/Immunology
J10-1 is a hapten. J10-1 promotes peptide exchange of all DR alleles (DR1, DR2, DR4 (DRB10401)) and promotes peptide binding to MHC II*, which can be used in the study of immune regulation .

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .

HY-P10382

M133 peptide	MHC	Inflammation/Immunology
M133 peptide is a coronavirus-specific CD4 T cell epitope. M133 peptide is immunodominant in mice infected with the neurotropic coronavirus (the JHM strain of mouse hepatitis virus). M133 peptide forms a complex with MHC II molecules, which is recognized by specific TCRs, thereby activating CD4 T cells .

HY-P99156

Relatlimab BMS-986016	LAG-3	Cancer
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC₅₀ value of 0.67 nM and LAG-3/FGL1 interaction with an IC₅₀ value of 0.019 nM. Relatlimab can be used in research of cancer .

HY-157992

LM-021	Interleukin Related Caspase Lactate Dehydrogenase Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
LM-021 is a coumarin-chalcone derivative with anti-aggregatory, antioxidant, neuroprotective and anti-inflammatory properties which suppresses nitric oxide (NO), IL-1β, IL-6, TNF-α production, CD68 antigen (CD68) and histocompatibility-2 (MHCII) expression. LM-021 also attenuates the increase of caspase 1 activity, lactate dehydrogenase release and ROS level. LM-021 can be used for neurological research .

Cat. No.	Product Name	Target	Research Area

HY-P10441A

S-palm P0(180–199) TFA 1 Publications Verification	Peptides	Inflammation/Immunology
S-palm P0(180–199) (TFA) is a peptide that enhances MHC II-restricted responses. S-palm P0(180–199) (TFA) can be used to establish models of chronic inflammatory demyelinating polyneuropathy (CIDP) and chronic experimental autoimmune neuritis (c-EAN). S-palm P0(180–199) (TFA) is used for studying autoimmune-mediated neuroinflammatory diseases .

HY-P5412

LLO (190-201) Listeriolysin O 190 peptide	Peptides	Others
LLO (190-201) (Listeriolysin O 190 peptide) is a biological active peptide. (This peptide is a major histocompatibility complex class II (MHC-II)-restricted peptide, LLO190 (NEKYAQAYPNVS), from the listeriolysin O protein of Listeria monocytogenes, which generates an LLO190-specific Th response. This peptide subsequently challenge recombinant L. monocytogenes expressing the MHC-I-restricted epitope of ovalbumin (Ova257, SIINFEKL).)

HY-P10835

LAG-3 cyclic peptide inhibitor C25	LAG-3	Cancer
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a K_d value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 ⁺ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .

HY-P10382

M133 peptide	MHC	Inflammation/Immunology
M133 peptide is a coronavirus-specific CD4 T cell epitope. M133 peptide is immunodominant in mice infected with the neurotropic coronavirus (the JHM strain of mouse hepatitis virus). M133 peptide forms a complex with MHC II molecules, which is recognized by specific TCRs, thereby activating CD4 T cells .

Cat. No.	Product Name	Target	Research Area

HY-P99027

Ieramilimab LAG525; IMP701	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .

HY-P99156

Relatlimab BMS-986016	LAG-3	Cancer
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC₅₀ value of 0.67 nM and LAG-3/FGL1 interaction with an IC₅₀ value of 0.019 nM. Relatlimab can be used in research of cancer .

HY-P99736

Miptenalimab BI-754111	LAG-3	Cancer
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (K_D: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.